Historically, these conditions have had considerably less funding and research, leading to a treatment landscape largely focused on reactive or end-stage disease management, often with significant physical, emotional, and financial burdens.
Our goal is to help patients living with kidney diseases by partnering with patients, advocates, clinicians, and policymakers to raise awareness, accelerate diagnosis, and get patients the care they need, sooner.
Immunoglobulin A nephropathy (IgAN) is a progressive, rare kidney disease in which the immune system damages the kidneys, often causing glomerular inflammation and proteinuria.1,2 With almost 13 out of every million people in the United States diagnosed per year, it is one of the most common primary autoimmune kidney diseases, and each person’s journey is unique.2,3 Up to 50% of IgAN patients progress to kidney failure within 10 to 20 years of diagnosis, often requiring maintenance dialysis and/or kidney transplantation.3-7
C3 glomerulopathy (C3G) is a progressive and ultra-rare kidney disease with the average age of diagnosis around 23 years old.8-10 Prognosis is poor, with approximately half of people living with C3G progressing to kidney failure within 10 years of diagnosis, requiring lifelong dialysis and/or kidney transplantation.8,11
Novartis researchers aim to preserve kidney function for patients.
References